Avadel Pharmaceuticals PLC Form 4 insider transactions

Avadel Pharmaceuticals' Chief Financial Officer, Thomas S. McHugh, purchased 5,000 ordinary shares at a price of $10.4865 per share on December 11, 2024.

Avadel Pharmaceuticals CEO, Gregory J. Divis, acquired shares through a revocable trust in multiple transactions.

Geoffrey Michael Glass, a co-trustee and sole beneficiary, has reported transactions involving Avadel Pharmaceuticals PLC ordinary shares held in trust.

Director Linda Palczuk of Avadel Pharmaceuticals PLC purchased 3,000 ordinary shares at a weighted average price of $10.1892.

Director Linda Palczuk reported transferring 11,000 stock options to a revocable trust on September 15, 2024.

Director Geoffrey Michael Glass transferred 11,000 stock options to a revocable trust on September 13, 2024.

Director Linda Palczuk acquired 11,000 ordinary shares and options in Avadel Pharmaceuticals on July 30, 2024.

Director Peter J. Thornton acquires 11,000 ordinary shares and 11,000 stock options in Avadel Pharmaceuticals.

Director Eric J Ende acquired 11,000 ordinary shares and 11,000 stock options in Avadel Pharmaceuticals on July 30, 2024.

Director Naseem Amin acquired 11,000 ordinary shares and options in Avadel Pharmaceuticals on July 30, 2024.

Mark Anthony McCamish, a director of Avadel Pharmaceuticals, acquired 11,000 ordinary shares and 11,000 stock options on July 30, 2024.

Director Geoffrey Michael Glass reports acquisition of Avadel Pharmaceuticals shares and options.

Director Naseem Amin acquired 49,500 stock options in Avadel Pharmaceuticals on May 17, 2024.

Richard J. Kim, Chief Commercial Officer of Avadel Pharmaceuticals, received stock options for 147,000 ADSs on February 20, 2024.

Thomas S. McHugh, CFO of Avadel Pharmaceuticals, was granted stock options for 157,500 ADSs on February 20, 2024.

Gregory J. Divis, CEO of Avadel Pharmaceuticals, was granted 600,000 stock options on February 20, 2024, according to a Form 4 filing.